Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Non-Muscle Invasive Bladder Neoplasms 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

Mitomycin 12Gemcitabine 9BCG Vaccine 4apaziquone 3Epirubicin 3erdafitinib 2durvalumab 2dodecyl maltoside 2VB4-845 2Docetaxel 2viscum album peptide 1valrubicin 1pirarubicin 1hydroxycamptothecinum 1Transurethral Resection of Bladder 1Therapeutic Uses 1Standard of Care 1Saline Solution 1Radiotherapy 1Polysorbates 1Maintenance 1Magnetic Resonance Spectroscopy 1Injections 1Cystoscopy 15-aminolevulinic acid hexyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Non-Muscle Invasive Bladder Neoplasms × dodecyl maltoside × Clear all
NCT04452591 2026-03-16

BOND-003

CG Oncology, Inc.

Phase 3 Active not recruiting
190 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT06111235 2026-01-12

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

CG Oncology, Inc.

Phase 3 Active not recruiting
367 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡